|
AU2007221981A1
|
|
Hematopoietic stimulation
|
|
WO2007117419A2
|
|
Methods and compositions relating to post-prolyl cleaving enzyme inhibitors
|
|
WO2007058957A2
|
|
Boroproline compound and cytokine combination therapy
|
|
AU2005211682A1
|
|
Anti-tumor comprising boroproline compounds
|
|
US2006094693A1
|
|
Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions
|
|
US2006063719A1
|
|
Methods for treating diabetes
|
|
AU2005201141A1
|
|
Stimulation of hematopoietic cells in vitro
|
|
WO2005071073A1
|
|
Fap compositions and the use thereof for immunomodulation
|
|
CN1826129A
|
|
Methods and compositions relating to isoleucine boroproline compounds
|
|
WO2004004658A2
|
|
Methods and compositions relating to isoleucine boroproline compounds
|
|
AU4062802A
|
|
Stimulation of hematopoietic cells in vitro
|
|
WO0071135A1
|
|
Anti-tumor comprising boroproline compounds
|
|
EP1806138A1
|
|
Anti-tumor agents comprising boroproline compounds
|
|
US6890904B1
|
|
Anti-tumor agents
|
|
US6979697B1
|
|
Regulation of substrate activity
|
|
IL141471D0
|
|
Regulation of substrate activity
|
|
EP1084129A1
|
|
Cyclic boroproline compounds
|
|
BR9910251A
|
|
Hematopoietic stimulation
|
|
WO9916864A1
|
|
Stimulation of hematopoietic cells in vitro
|
|
IL159948D0
|
|
Stimulation of hematopoietic cells in vitro
|
